Comparison of healthcare costs among patients with non ‐valvular atrial fibrillation treated with warfarin who switched to a novel oral anticoagulant
ConclusionsOutpatient costs were considerably lower among dabigatran switchers compared with rivaroxaban. Total and OP healthcare costs were significantly lower for patients switching from warfarin to dabigatran versus apixaban. Use of dabigatran following warfarin discontinuation may enable healthcare cost savings among NVAF patients, as compared with rivaroxaban or apixaban.
Source: Journal of Pharmaceutical Health Services Research - Category: Drugs & Pharmacology Authors: Jessica Franchino ‐Elder,
Adrienne Gilligan,
Xue Song,
Briain O Hartaigh,
Caroline Henriques,
Amy Sainski‐Nguyen,
Cheng Wang Tags: Research Paper Source Type: research
More News: Atrial Fibrillation | Coumadin | Databases & Libraries | Drugs & Pharmacology | Emergency Medicine | Healthcare Costs | Pradaxa | Warfarin